Want to see JP:4881 full AI Analyst Report?

FunPep Company Limited (4881) Price & Analysis

0 Followers

4881 Stock Chart & Stats

¥79.00

¥1.00(0.72%)

At close: Jan 08 4:00 PM EST

¥79.00

¥1.00(0.72%)

Day’s Range― - ―

52-Week Range¥45.00 - ¥130.00

Previous CloseN/A

Volume532.20K

Average Volume (3M)245.82K

Market Cap

¥2.53B

Enterprise Value¥1.49K

Total Cash (Recent Filing)¥1.87B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-39.76

Shares Outstanding50,666,700

10 Day Avg. Volume262,310

30 Day Avg. Volume245,823

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)2.13

Price to Sales (P/S)9943.96

P/FCF Ratio-2.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-19.9

Revenue Forecast (FY)¥300.00M

Bulls Say, Bears Say

Bulls Say

Clean Balance Sheet (zero Debt)A zero-debt capital structure materially reduces near-term refinancing risk and gives management flexibility to pursue partnerships, milestone-focused R&D or staged financing. For an early-stage biotech this durable low leverage extends runway and preserves optionality amid negative cash flow.

Prior Free Cash Flow ImprovementImproved free cash flow in 2023–2024 indicates the company has shown the ability to tighten spending or realize episodic cash inflows. In a cyclical biotech model, demonstrated prior FCF improvement supports the possibility of re-establishing healthier cash generation through cost discipline or milestone receipts over a multi-month horizon.

Lean Operating FootprintA very small headcount implies a low fixed-cost base and operational agility, which helps conserve cash and simplify partnership or outsourcing strategies. Over the medium term this lean structure can extend runway, reduce the pace of dilution, and make resource reallocation easier as milestones dictate.

Bears Say

Severe Revenue CollapseA ~94% year‑over‑year revenue decline signals a structurally weak or volatile commercial foundation, undermining durable revenue predictability. Such a collapse reduces internal funding for R&D and commercialization, weakens negotiating leverage with partners, and raises questions about sustainable market position.

Accelerating Operating Cash BurnOperating cash flow more than doubled its negative outflow in 2025, reflecting accelerating cash consumption. Persistent negative OCF means the business is not self-funding, elevating financing and dilution risk. Without durable cash generation or secured partner funding, runway and strategic optionality are constrained.

Widening Losses And Equity ErosionSubstantially larger net losses and a meaningful fall in shareholder equity over several years signal ongoing value erosion. This weakens the company’s capital buffer, increases dependency on external financing, and raises the probability of dilutive raises or strategic restructuring over the medium term.

4881 FAQ

What was FunPep Company Limited’s price range in the past 12 months?

FunPep Company Limited lowest stock price was ¥45.00 and its highest was ¥130.00 in the past 12 months.

What is FunPep Company Limited’s market cap?

FunPep Company Limited’s market cap is ¥2.53B.

When is FunPep Company Limited’s upcoming earnings report date?

FunPep Company Limited’s upcoming earnings report date is Nov 18, 2026 which is in 94 days.

How were FunPep Company Limited’s earnings last quarter?

FunPep Company Limited released its earnings results on Aug 14, 2026. The company reported -¥5.63 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is FunPep Company Limited overvalued?

According to Wall Street analysts FunPep Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FunPep Company Limited pay dividends?

FunPep Company Limited does not currently pay dividends.

What is FunPep Company Limited’s EPS estimate?

FunPep Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FunPep Company Limited have?

FunPep Company Limited has 50,666,700 shares outstanding.

What happened to FunPep Company Limited’s price movement after its last earnings report?

FunPep Company Limited reported an EPS of -¥5.63 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.041%.

Which hedge fund is a major shareholder of FunPep Company Limited?

Currently, no hedge funds are holding shares in JP:4881

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FunPep Company Limited

FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.